Arthrex SpeedFLEX™ Implant

K251690 · Arthrex, Inc. · OWY · Sep 30, 2025 · General, Plastic Surgery

Device Facts

• Record ID: K251690
• Device Name: Arthrex SpeedFLEX™ Implant
• Applicant: Arthrex, Inc.
• Product Code: OWY · General, Plastic Surgery
• Decision Date: Sep 30, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.3300
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Arthrex SpeedFLEX™ Implant is intended for use in general surgical procedures for reinforcement of soft tissue where weakness exists. The Arthrex SpeedFLEX™ Implant is also intended for reinforcement of soft tissues that are repaired by suture or suture anchors, during tendon repair surgery including but not limited to reinforcement of rotator cuff, patellar, Achilles, biceps, or quadriceps tendons. The Arthrex SpeedFLEX™ Implant is not intended to replace normal body structures or provide the full mechanical strength to support the rotator cuff, patellar, Achilles, biceps, or quadriceps tendons. Sutures used to repair the tear, and sutures or bone anchors used to attach the tissue to bone, provide mechanical strength for the tendon repair.

Device Story

Decellularized human allograft dermis implant; pre-sutured with FiberWire® (passing) and TigerLink™ SutureTape (implanted). Used in surgical settings by surgeons to reinforce soft tissue defects or tendon repairs. Implant provides biological scaffold; mechanical strength provided by surgeon-applied sutures and bone anchors. Sterile, single-use device. Benefits include soft tissue reinforcement during repair procedures. Clinical decision-making supported by surgeon assessment of tissue weakness and repair requirements.

Clinical Evidence

Bench testing included biomechanical (tensile, suture retention) and Bacterial Endotoxin Testing (BET) per ANSI/AAMI ST72:2019, USP <161>, USP <85>. Biocompatibility testing per ISO 10993-1:2018 (cytotoxicity, sensitization, irritation, genotoxicity, systemic toxicity, implantation, material-mediated pyrogenicity). Clinical evidence consists of 22 peer-reviewed human clinical studies evaluating the components (decellularized dermis, TigerLink SutureTape, FiberWire) in similar surgical applications, supporting analogous safety and performance to predicate.

Technological Characteristics

Decellularized human allograft dermis; pre-sutured with FiberWire and TigerLink SutureTape. Sterilized to SAL 10^-6. Complies with 21 CFR 1270/1271 and AATB standards for tissue banking. Biocompatible per ISO 10993-1:2018.

Indications for Use

Indicated for reinforcement of soft tissue in general surgical procedures where weakness exists, and for reinforcement of soft tissues repaired by suture or suture anchors during tendon repair surgery (e.g., rotator cuff, patellar, Achilles, biceps, or quadriceps tendons). Not intended to replace normal body structures or provide full mechanical strength for tendon repair.

Regulatory Classification

Identification

Surgical mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair, and acetabular and cement restrictor mesh used during orthopedic surgery.

Predicate Devices

• Medeor™ Matrix (K103787)

Reference Devices

• MTF Fascia (K120479)
• FiberWire® suture (K021434)
• TigerLink™ SutureTape (K122374)

Submission Summary (Full Text)

{0}

FDA U.S. FOOD &amp; DRUG ADMINISTRATION

September 30, 2025

Arthrex Inc.
Emmarie Halteman
Senior Regulatory Affairs Specialist
1370 Creekside Boulevard
Naples, Florida 34108

Re: K251690
Trade/Device Name: Arthrex SpeedFLEX™ Implant
Regulation Number: 21 CFR 878.3300
Regulation Name: Surgical Mesh
Regulatory Class: Class II
Product Code: OWY, GAT
Dated: August 29, 2025
Received: August 29, 2025

Dear Emmarie Halteman:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

U.S. Food &amp; Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K251690 - Emmarie Halteman
Page 2

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-

{2}

K251690 - Emmarie Halteman
Page 3

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

CHRISTOPHER FERREIRA -S

Christopher Ferreira, M.S.
Assistant Director
DHT6C: Division of Restorative,
Repair, and Trauma Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

{3}

Arthrex SpeedFLEX™ Implant
Page 8 of 39

| Indications for Use | | |
| --- | --- | --- |
| Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K251690 | ? |
| Please provide the device trade name(s). | | ? |
| Arthrex SpeedFLEX™ Implant | | |
| Please provide your Indications for Use below. | | ? |
| The Arthrex SpeedFLEX™ Implant is intended for use in general surgical procedures for reinforcement of soft tissue where weakness exists. The Arthrex SpeedFLEX™ Implant is also intended for reinforcement of soft tissues that are repaired by suture or suture anchors, during tendon repair surgery including but not limited to reinforcement of rotator cuff, patellar, Achilles, biceps, or quadriceps tendons. The Arthrex SpeedFLEX™ Implant is not intended to replace normal body structures or provide the full mechanical strength to support the rotator cuff, patellar, Achilles, biceps, or quadriceps tendons. Sutures used to repair the tear, and sutures or bone anchors used to attach the tissue to bone, provide mechanical strength for the tendon repair. | | |
| Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? |

{4}

Arthrex

K251690

# 510(k) Summary

| Date Prepared | 5/30/2025 |
| --- | --- |
| Submitter | Arthrex Inc.
1370 Creekside Boulevard
Naples, FL 34108-1945 |
| Contact Person | Name: Emmarie Halteman
Title: Senior Regulatory Affairs Specialist
Phone: [phone] ext. 74232
Email: [e-mail] |
| Trade Name | Arthrex SpeedFLEX™ Implant |
| Common Name | Mesh, Surgical, Collagen, Orthopaedics, Reinforcement of Tendon |
| Product Code | Primary: OWY
Additional: GAT |
| Classification Name | CFR 878.3300: Mesh, Surgical, Collagen, Orthopaedics, Reinforcement of Tendon
CFR 878.5000: Nonabsorbable poly(ethylene terephthalate) surgical suture |
| Regulatory Class | Class II |
| Primary Predicate Device | K103787: Medeor™ Matrix |
| Reference Device | K120479: MTF Fascia |
| Purpose of Submission | This Traditional 510(k) premarket notification is submitted to obtain clearance for the Arthrex SpeedFLEX™ Implant. |
| Device Description | The Arthrex SpeedFLEX™ Implant consists of a decellularized human allograft dermis that is pre-sutured with FiberWire® suture (passing suture) and TigerLink™ SutureTape (implanted). The allograft implant will be offered in four (4) sizes. The Arthrex SpeedFLEX™ Implant is sold sterile, single use. |
| Indications for Use | The Arthrex SpeedFLEX™ Implant is intended for use in general surgical procedures for reinforcement of soft tissue where weakness exists. The Arthrex SpeedFLEX™ Implant is also intended for reinforcement of soft tissues that are repaired by suture or suture anchors, during tendon repair surgery including but not limited to reinforcement of rotator cuff, patellar, Achilles, biceps, or quadriceps tendons. The Arthrex SpeedFLEX™ Implant is not intended to replace normal body structures or provide the full mechanical strength to support the rotator cuff, patellar, Achilles, biceps, or quadriceps tendons. Sutures used to repair the tear, and sutures or bone anchors used to attach the tissue to bone, provide mechanical strength for the tendon repair. |
| Performance Data | The subject device Arthrex SpeedFLEX™ Implant consists of a decellularized human allograft dermis that is pre-sutured with FiberWire® suture (passing suture) and TigerLink™ SutureTape (implanted). The submitted biomechanical test data, Tensile and |

Page 1 of 3

{5}

Arthrex
K251690

| | Suture Retention, was performed to address the risks of decreased biomechanical strength of the suture materials in the subject device Arthrex SpeedFLEX™ Implant.

Bacterial Endotoxin Testing (BET) was performed on the Arthrex SpeedFLEX implant utilizing the Kinetic Chromogenic Method in accordance with ANSI/AAMI ST72:2019, USP <161>, USP <85>. Testing was performed in compliance with US FDA good manufacturing practice (GMP) regulations 21 CFR Parts 210, 211 and 820. The testing conducted demonstrates that the Arthrex SpeedFLEX implant meets pyrogen limit specifications.

All donors have been screened and tissues recovered, processed, stored, tested, and distributed in accordance with current U.S. federal regulations as promulgated in 21 CFR 1270 and 1271, current Standards for Tissue Banking set forth by the American Association of Tissue Banks (AATB) and international laws and regulations as required. This allograft was deemed suitable for implantation by LifeNet Health. A physician medical director evaluated the following donor variables to determine donor suitability: infectious disease test results, current donor medical history, behavioral risk assessment interview, physical assessment, relevant medical records, including previous medical history, laboratory test results, and autopsy or coroner reports (if performed). All donors are tested for relevant infectious diseases. Testing is performed by laboratories that are registered with the U.S. Food and Drug Administration (FDA) and certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR 493. Test methods that are FDA-licensed, approved, or cleared for donor screening are used as available. The following test criteria were met for the donor of this allograft bio-implant: Hepatitis B virus (HBV) surface antigen, HBV core antibody, Hepatitis C virus (HCV) antibody, HIV-1/12 antibody, Syphilis, HIV-1 NAT, HCT NAT, and HBV NAT.

Cytotoxicity, Sensitization, Irritation, Genotoxicity, Acute Systemic Toxicity, Implantation, Material Mediated Pyrogenicity, and Material Chemical Characterization was conducted on the Arthrex SpeedFLEX™ implant in accordance with ISO 10993-1:2018 and deemed biocompatible when used as intended. |
| --- | --- |
| Technological Comparison | Compared to the predicate device Medeor™ Matrix (K103787), the subject Arthrex SpeedFLEX™ Implant has the same fundamental scientific technology, sterility, and shelf-life. The subject Arthrex SpeedFLEX™ Implant is comprised of decellularized human allograft dermis that is pre-sutured with FiberWire® suture (K021434) and TigerLink™ SutureTape (K122374); whereas the predicate device is composed of decellularized porcine-dermis-derived collagen |

Page 2 of 3

{6}

Arthrex
K251690

| | surgical mesh and is not pre-sutured. Additionally, the reference device MTF Fascia (K120479) surgical mesh is made of decellularized human allograft and complies with all requirements in 21 CFR 1271 to reduce the risk of the introduction, transmission, and spread of communicable diseases by human cells, tissues, and cellular and tissue-based products (HCT/Ps) analogously to the Arthrex SpeedFLEX™ Implant. Both the predicate and subject devices are sterilized to a sterility assurance level of 10^{-6}. Any differences between the subject device and the predicate device are considered minor and do not raise new or different questions concerning safety or effectiveness.

The submitted biomechanical test data demonstrates that the Arthrex SpeedFLEX™ Implant results are statistically equivalent to the predicate device Medeor™ Matrix (K103787) for the desired indications.

The predicate device submitted two in vivo animal studies (sheep and rabbit) to assess the tissue response when used to repair a defect. For the subject device, the results of 22 peer-reviewed human clinical data, inclusive of local tissue response for the subject device when the three components (decellularized dermis, TigerLink SutureTape, and FiberWire suture) are assembled in the operating room by the surgeon to repair the indicated defects. The data supports an analogous conclusion to the predicate.

Based on the fundamental scientific technology and the summary of data submitted, Arthrex Inc. has determined that the subject device is substantially equivalent to the currently marketed predicate device Medeor™ Matrix (K103787). |
| --- | --- |
| Conclusion | The Arthrex SpeedFLEX™ Implant is substantially equivalent to the predicate device in which the intended orthopedic use/indications (OHT6) are the same. Any difference between the subject device and the predicate device are considered minor and do not raise different questions concerning safety or effectiveness. Based on the indications for use, technological characteristics, and the summary of data submitted, Arthrex Inc. has determined that the subject device is substantially equivalent to the currently marketed predicate device. |

Page 3 of 3